CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Valcyte (valganciclovir) coverage criteria for cytomegalovirus (CMV)

Defines medical necessity and authorization criteria for Valcyte (valganciclovir) for treatment and prevention of cytomegalovirus (CMV) across FDA-approved and compendial indications for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyValcyte (valganciclovir) coverage criteria for CMV

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and submit documentation showing the member meets an FDA-approved or accepted compendial indication; up to 12 months may be authorized for listed indications.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsstandard authorization duration for most indications

3 populationsFDA-approved indications listed

5 usesCompendial/other listed uses

Genentech PIPrimary product reference

Coverage Criteria for Valcyte (valganciclovir)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

COVERAGE CRITERIA — Covered Indications

Covered when the member meets an FDA‑approved indication or an accepted compendial use and has no exclusions to the prescribed therapy.

ALL of the following

The requested use is for an FDA‑approved indication for Valcyte (valganciclovir): 1. Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); or 2. Prevention of CMV disease in kidney, heart, and kidney‑pancreas transplant patients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-]); or 3. Prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.
Source: FDA‑approved indications.
OR the requested use is an accepted compendial use for Valcyte (valganciclovir), including: 1. Prevention of CMV infection in adult and pediatric patients post solid organ transplant or post hematopoietic stem cell transplant (HSCT); 2. Treatment of CMV infection in solid organ transplant recipients; 3. Symptomatic congenital cytomegalovirus infection; 4. Treatment of CMV gastrointestinal disease in human immunodeficiency virus (HIV) infection; 5. Multicentric Castleman's disease, human herpesvirus‑8 positive.
Source: Recognized compendial uses.
There are no member exclusions to the prescribed therapy (e.g., contraindications, formulary exclusions).
Operational requirement.

Initial and Continuation Authorization

Authorization periods and rules for initial and continuation therapy.

ALL of the following

Initial and Continuation Authorization
- Initial authorization: Authorization of up to 12 months may be granted for eligible indications as described in the coverage criteria (Section I), including induction or maintenance treatment of CMV retinitis in HIV‑infected members; treatment of CMV gastrointestinal disease in HIV‑infected members; prevention of CMV infection in post solid organ transplant or post HSCT patients (prophylaxis or preemptive); treatment of mild to moderate CMV infection in solid organ transplant recipients; treatment of symptomatic congenital CMV infection; and treatment of multicentric Castleman's disease in HHV‑8 positive members.
  Initial authorization duration: 12 months where indicated.
- Continuation of therapy: Authorization of up to 12 months may be granted for continued treatment when either: A. For symptomatic congenital CMV infection: the member meets all initial authorization criteria and has received less than 12 months of therapy; or B. For all other indications: the member continues to meet all initial authorization criteria.
  Continuation requires meeting initial criteria or treatment duration limits.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required — Duration & Scope

Authorization of up to 12 months may be granted for treatment or prevention for listed indications. Prior authorization is required before services are rendered.

Authorization duration: up to 12 months for induction, maintenance, prevention (prophylaxis or preemptive), and continuation of therapy when criteria are met.
Applicable indications: treatment of CMV infection in HIV-infected patients (including CMV retinitis and CMV GI disease), prevention of CMV infection post solid organ transplant or post HSCT, treatment of CMV infection in solid organ transplant recipients, symptomatic congenital CMV infection, and multicentric Castleman’s disease (HHV-8 positive).
Reauthorization: up to 12 months may be granted for continuation when initial criteria are met (see continuation criteria).

Documentation Required

Providers must submit documentation that supports the member meets FDA‑approved or recognized compendial indications and aligns with product labeling or authoritative guidelines.

Include relevant clinical notes, diagnostic test results, transplant date (if applicable), HIV status and history for HIV‑related indications, CMV viral load or tissue diagnosis for CMV disease, and prior treatment history.
Reference supporting labeling or compendia (e.g., Valcyte package insert, NCCN Compendium, Micromedex, Lexi‑Comp) when the use is compendial.
For congenital CMV, include neonatal findings and hearing evaluations as applicable.

Denial Risk

Experimental / Investigational — Exclusions

Indications not listed as covered (including uses outside FDA‑approved or recognized compendial indications) are considered experimental/investigational and are not medically necessary. Such requests will be denied unless compelling evidence is provided and coverage criteria are met.

All requests for indications not explicitly listed (or supported by recognized compendia) will be reviewed as investigational and are typically denied.
If requesting coverage for an unlisted indication, include strong supporting clinical evidence and rationale referencing peer‑reviewed literature or authoritative guidelines.

Note

Provider Requirements / Action

Provider action: submit a complete prior authorization request with supporting documentation and anticipate a single authorization period of up to 12 months when criteria are met.

Ensure all required clinical information and references to product labeling or compendia are included to avoid delays or denial.
For reauthorization requests, document response to therapy and that the member continues to meet initial authorization criteria.

OpenPayer

Valcyte (valganciclovir) coverage criteria for cytomegalovirus (CMV)

Coverage Criteria for Valcyte (valganciclovir)

Provider Actions, Authorization & Documentation

Coding and Policy Reference

Key Definitions

Background